Extended-release niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CAD

Journal of Clinical Lipidology

Volumn 3, Issue 1, 2009, Pages 45-50

  Jafri, Haseeb ^a   Alsheikh Ali, Alawi A ^a   Mooney, Paula ^a   Kimmelstiel, Carey D ^a   Karas, Richard H ^a   Kuvin, Jeffrey T ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Extended release niacin; HDL; LDL; Lipid profile; Particle number; Stable coronary artery disease

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NITRATE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 59249088706     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2008.12.003     Document Type: Article

References (19)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
2. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
3. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 345 (2001) 1583-1592
4. Miller B.D., Alderman E.L., Haskell W.L., Fair J.M., and Krauss R.M. Predominance of dense low-density lipoprotein particles predicts angiographic benefit or therapy in the Stanford Coronary Risk Intervention project. Circulation 94 (1996) 2146-2153
5. Miller B.D., Krauss R.M., Cashin-Hemphill L., and Blankenhorn D.H. Baseline triglyceride levels predict angiographic benefit of colestipol plus niacin therapy in the Cholesterol-Lowering Atherosclerosis Study (CLAS). (abstr). Circulation 88 (1993) I-363
6. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 8 (1986) 1245-1255
7. Kuvin J., Patel A., Ramet M., et al. Novel mechanisms for the beneficial vascular effects of HDL cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 144 (2002) 165-172
8. Morgan J.M., Capuzzi D.M., Baksh R.I., et al. Effects of extended release niacin on lipoprotein subclass profile. Am J Cardiol 91 (2003) 1432-1436
9. Superko H.R., and Krauss R.M. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 95 (1992) 69-76
10. Mora S., Szklo M., Otvos J.D., et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 192 (2006) 211-217
11. Otvos J.D., Collins D., Freedman D.S., et al. Low-density lipoprotein and high density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Denisty Lipoprotein Intervention Trial. Circulation 113 (2006) 1556-1563
12. Brunzel J.D., Davidson M., Furberg C.D., et al. Lipoprotein management in patients with cardiometabolic risk: Consensus Conference Report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 51 (2008) 1512-1524
13. Austin M.A., Breslow J.L., Hennekens C.H., et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260 (1988) 1917-1921
14. Gardner C.D., Fortmann S.P., and Krauss R.M. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276 (1996) 875-881
15. Johansson J., Carlson L.A., Landou C., and Hamsten A. High density lipoproteins and coronary atherosclerosis: a strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 11 (1991) 174-182
16. Sanyal S., Karas R.H., and Kuvin J.T. Present-day uses of niacin: effects on lipid and non-lipid parameters. Expert Opin Pharmacother 11 (2007) 1711-1717
17. McKenney J.M., McCormick L.S., Schaefer E.J., Black D.M., and Watkins M.L. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 88 (2001) 270-274
18. Morgan J.M., Capuzzi D.M., Baksh R.I., et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 91 (2003) 1432-1436
19. Kuvin J.T., Devang M.D., Sliney K.A., et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 98 (2006) 743-745